Hypermethylation of the CHRDL1 promoter induces proliferation and metastasis by activating Akt and Erk in gastric cancer

Yao-fei Pei; Ya-jing Zhang; Yao Lei; Ding-wei Wu; Tong-hui Ma; Xi-qiang Liu

doi:10.18632/oncotarget.15513

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

This article has been corrected. Correction in: Oncotarget. 2017; 8:48526.

Hypermethylation of the CHRDL1 promoter induces proliferation and metastasis by activating Akt and Erk in gastric cancer

Yao-fei Pei, Ya-jing Zhang, Yao Lei, Ding-wei Wu, Tong-hui Ma and Xi-qiang Liu _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2017; 8:23155-23166. https://doi.org/10.18632/oncotarget.15513

Metrics: PDF 2242 views | HTML 2516 views | ?

Abstract

Yao-fei Pei1,*, Ya-jing Zhang2,*, Yao Lei3, Ding-wei Wu1, Tong-hui Ma4, Xi-qiang Liu1

1Department of Hepatobiliary-Pancreatic Surgery, Zhejiang Provincial People’s Hospital, Hangzhou, Zhejiang Province 310014, PR China

2Department of General Surgery, Bejing Anzhen Hospital, Capital Medical University, Beijing 100000, PR China

3Department of Interventional Therapy and Vascular Surgery, Hunan Provincial People’s Hospital, Changsha, Hunan Province 410005, PR China

4Genetron Health (Beijing) Technology, Co. Ltd., Changping, Beijing 100000, PR China

*These authors contributed equally to this work

Correspondence to:

Xi-qiang Liu, email: [email protected]

Keywords: CHRDL1, EMT, gastric cancer, methylation, Wnt

Received: December 08, 2016 Accepted: February 07, 2017 Published: February 19, 2017

ABSTRACT

CHRDL1 (Chordin-like 1) is a secreted protein that acts as an antagonist of bone morphogenetic protein (BMP). BMP plays a role as an activator of BMP receptor II (BMPR II), which mediates extracellular to intracellular signal transmission and is involved in carcinogenesis and metastasis. Herein, we report that CHRDL1 expression was significantly down-regulated in gastric cancer tissues and associated with poor survival. Clinic-pathological parameters demonstrated a close relationship between low CHRDL1 expression and metastasis. In vitro, CHRDL1 knockdown promoted tumor cell proliferation and migration through BMPR II by activating Akt, Erk and β-catenin. Furthermore, we observed the hypermethylation of the CHRDL1 promoter in gastric cancer, which induced low expression of CHRDL1 and decreased its secretion to the supernatant. Finally, in vivo experiments confirmed that CHRDL1 acted as a tumor suppressor gene in suppressing tumor growth and metastasis.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 15513

Publication Alerts

Research Papers:

Hypermethylation of the CHRDL1 promoter induces proliferation and metastasis by activating Akt and Erk in gastric cancer

Abstract